ELI LILLY AND COMPANY |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 844.8 USD | +1.57% |
|
+3.43% | +44.62% |
| 03:36pm | US FDA panel to vote on data, risk profile of Lilly Alzheimer's drug | RE |
| 01:00am | Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China | RE |
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
831.8
USD
Average target price
852.5
USD
Spread / Average Target
+2.50%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +44.62% | 749B | |
| +39.08% | 605B | |
| -6.48% | 351B | |
| +20.03% | 328B | |
| +7.96% | 292B | |
| +11.74% | 216B | |
| -2.49% | 214B | |
| +2.03% | 167B | |
| +7.38% | 165B | |
| +1.16% | 123B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- UBS Adjusts Eli Lilly and Company Price Target to $381 From $363, Maintains Buy Rating
